Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 719

Sort by

Sort Order Select

Journal Articles

Platelet RNA Splicing Profiles Can Distinguish IgM MGUS Patients from Healthy Individuals

Mick J.M. Van Eijs, MSc, Nicolette C. Notermans, MD PhD, Tom Würdinger, PhD, Monique C. Minnema, MD PhD

Blood (2019) 134 (Supplement_1): 3771.

https://doi.org/10.1182/blood-2019-124325

Published: 2019

Journal Articles

Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status

Agrima Mian, MBBS, MD, Albert Aboseif, DO, Wei Wei, MS, Rajshekhar Chakraborty, MD, Jack Khouri, MD, Joslyn Rudoni, PharmD, Allison M. Winter, MD, Sonam Patel, MD, Deepa Jagadeesh, MDMPH, Robert M. Dean, MD, Brad Pohlman, MD, Stephanie Berg, DO, James R. Cook, MD PhD, Brian T. Hill, MD, Alex V. Mejia Garcia, MD

Blood (2019) 134 (Supplement_1): 5248.

https://doi.org/10.1182/blood-2019-130396

Published: 2019

Journal Articles

Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE

Silvia Mangiacavalli, Zacchino Michela, MD, Virginia Valeria Ferretti, Claudio Salvatore Cartia, MD, Giovanni Savietto, MD, Pietro Benvenuti, MD, Marzia Varettoni, Sara Rattotti, Brociner Marco, Gabriele Merati, MD, Luca Arcaini

Blood (2019) 134 (Supplement_1): 5495.

https://doi.org/10.1182/blood-2019-126422

Published: 2019

Journal Articles

Prevalence of Monoclonal Gammopathy of Undetermined Significance in a Large Population with Annual Physical Examination in Beijing, China

Jinuo Wang, MD, Jian-Hua Han, Yue-lun Zhang, Xin-xin Cao, Dao-Bin Zhou, Teng-da Xu, Wei Su, Jian Li, MD

Blood (2019) 134 (Supplement_1): 5519.

https://doi.org/10.1182/blood-2019-124715

Published: 2019

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Agoston Gyula Szabo, MD, Jonathan Thorsen, MD PhD, Charlotte Toftmann Hansen, MD PhD, Maja Ølholm Vase, MD PhD, Manuela Teodorescu, MD, Simon Bo Pedersen, MD, Simon Bertram Flæng, MD, Ulf Christian Frølund, MD, Annette Juul Vangsted, MD PhD, Torben Plesner, MD DSc

Blood (2019) 134 (Supplement_1): 5553.

https://doi.org/10.1182/blood-2019-124336

Published: 2019

Journal Articles

Update on Risk Stratification Model of Smoldering Multiple Myeloma: A Systematic Review

Saad Ullah Malik, MD, Ahmad Abu-Hashyeh, MBBS, Muhammad Sardar, MD, Mohammad M Alhousani, Emilia Cindy Leigh, MD, Mohamed Suliman, MD, Abdul Mughees Rana, MD, Samson Teka, Eva Tackett, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5512.

https://doi.org/10.1182/blood-2019-132260

Published: 2019

Journal Articles

Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition

Blood (2019) 134 (Supplement_1): 3080.

https://doi.org/10.1182/blood-2019-131835

Published: 2019

Journal Articles

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Amandeep Godara, MD, Denis Toskic, BS, Benjamin Rosenthal, BS, Cindy Varga, MD BSc, Adin Kugelmass, BSc, Ping Zhou, MD PhD, Teresa Fogaren, NP, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4369.

https://doi.org/10.1182/blood-2019-127004

Published: 2019

Journal Articles

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Sneha Purvey, MD, Kenneth Seier, MS, Sean M. Devlin, PhD, Josel D Ruiz, MPH, Molly A. Maloy, MS, Gunjan L. Shah, MDMS, Hani Hassoun, MD, Sergio A. Giralt, MD, Heather J Landau, MD

Blood (2019) 134 (Supplement_1): 4577.

https://doi.org/10.1182/blood-2019-129195

Published: 2019

Journal Articles

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Faye Amelia Sharpley, BA MA MSc MBBChir FRCPath, Hannah Victoria Giles, FRCPath, MRCP, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Carol J Whelan, Philip N Hawkins, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 4375.

https://doi.org/10.1182/blood-2019-128175

Published: 2019

Journal Articles

Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone

Slavisa Ninkovic, MBBS FRACP FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Lenny Straszkowski, BSci Hons, Giulia Quattrocchi, Wee-Joo Chng, MBBS, PhD, Louise E Purton, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD

Blood (2019) 134 (Supplement_1): 4376.

https://doi.org/10.1182/blood-2019-128190

Published: 2019

Journal Articles

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Marion Eveillard, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Eric L Smith, MD PhD, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X Lu, MD PhD, Neha Korde, MD, Ola Landgren, MD PhD, Katie Thoren, PhD

Blood (2019) 134 (Supplement_1): 4377.

https://doi.org/10.1182/blood-2019-128938

Published: 2019

Journal Articles

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Blood (2019) 134 (Supplement_1): 3034.

https://doi.org/10.1182/blood-2019-128850

Published: 2019

Journal Articles

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

Andrew Spencer, DM, Tiffany Khong, BSc, PhD, Flora Yuen, BBiomedSc, Hannah Victoria Giles, FRCPath, MRCP, Malgorzata Gorniak, BSc, Hang Quach, MBBS, FRACP, FRCPA, MD, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP,FRCPA,MPhil,BA, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Krystal Bergin, Shreerang Sridesai, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, John Reynolds, PhD

Blood (2019) 134 (Supplement_1): 3090.

https://doi.org/10.1182/blood-2019-129760

Published: 2019

Journal Articles

Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min

Karthik Ramasamy, MBBS MRCP FRCPath PhD, Mark T Drayson, MB ChB, PhD FRCPath, Gulnaz Iqbal, PhD, Victoria Stalker, BSc, MA, Salma Akhtar, BSc, MSc, Janet Dunn, PhD, Stephen Schey, MBBS

Blood (2019) 134 (Supplement_1): 3135.

https://doi.org/10.1182/blood-2019-128157

Published: 2019

Journal Articles

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Victoria R. Alegria, Salman Ahmed, MD, Betsy Laplant, MS, Alak Manna, PhD, Ricardo Parrondo, MD, Vivek Roy, MD, Taimur Sher, MD, Brett Edwards, Stephanie Lanier, Keisha Jackson, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2019) 134 (Supplement_1): 3137.

https://doi.org/10.1182/blood-2019-128610

Published: 2019

Journal Articles

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Dennis Cooper, MD, Deepu Madduri, MD, Suzanne Lentzsch, MD PhD, Sundar Jagannath, Jingjin Li, PhD, Anita Boyapati, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Min Zhu, PhD, Israel Lowy, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Manish Sharma, MD, Maria Karasarides, PhD, David Sternberg, MD PhD

Blood (2019) 134 (Supplement_1): 3176.

https://doi.org/10.1182/blood-2019-126818

Published: 2019

Journal Articles

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

Vikram Premkumar, MD, Suzanne Lentzsch, MD PhD, Divaya Bhutani, MD

Blood (2019) 134 (Supplement_1): 3161.

https://doi.org/10.1182/blood-2019-123496

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

NARROW

Platelet RNA Splicing Profiles Can Distinguish IgM MGUS Patients from Healthy Individuals

Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status

Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE

Prevalence of Monoclonal Gammopathy of Undetermined Significance in a Large Population with Annual Physical Examination in Beijing, China

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Update on Risk Stratification Model of Smoldering Multiple Myeloma: A Systematic Review

Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only